Sugi Predict

Sugi Predict / Compounds / SCHEMBL365156

SCHEMBL365156

SCHEMBL365156

COC(=O)c1csc(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.45
▸ CA2 P00918 4/20 0.45
▸ CA12 O43570 3/20 0.45
▸ CA7 P43166 3/20 0.45
▸ CA9 Q16790 3/20 0.45
▸ CA14 Q9ULX7 3/20 0.45
▸ KDM4E B2RXH2 4/20 0.44
▸ XDH P47989 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ FUT7 Q11130 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ NOTUM Q6P988 2/20 0.42
▸ TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938203 0.79 CA12 (0.50) CA1CA2CA12CA7CA9
SCHEMBL29473506 0.79 CA1 (0.48) CA1CA2CA12CA7CA9
SCHEMBL7372827 0.78 DAO (0.61) CA1CA2CA12CA7CA9
SCHEMBL70248 0.78 CA1 (0.47) CA1CA2CA12CA7CA9
SCHEMBL1820040 0.77 — —
SCHEMBL27682287 0.76 CES2 (0.39) CA2TDP1LMNATSHRALDH1A1
SCHEMBL15057183 0.76 CA1 (0.45) CA1CA2CA12CA7CA9
SCHEMBL19127835 0.76 DAO (0.59) CA1CA2CA12CA7CA9
SCHEMBL31087127 0.76 CA1 (0.45) CA1CA2CA12CA7CA9
SCHEMBL7892513 0.76 DAO (0.53) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2026-01-08 — — US disclosed
CN-113072546-B Five-membered heteroaromatic derivative and preparation method and application thereof 广东东阳光药业股份有限公司 2025-05-30 — — CN disclosed
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4536350-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2025-04-16 — — EP disclosed
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 — — CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 — — EP disclosed
CN-119241504-A Spiroindoline inhibitors of KIF18A 沃拉斯查疗法公司 2025-01-03 — — CN disclosed
US-20240368096-A1 Fused Heterobicyclic Antiviral Agents ENANTA PHARMACEUTICALS, INC. 2024-11-07 — — US disclosed
US-20240351984-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A VOLASTRA THERAPEUTICS, INC. (US) 2024-10-24 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 — — US disclosed
CN-100584840-C Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB 2010-01-27 — — CN disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 — — WO disclosed
WO-2009112845-A1 AMIDO-THIOPHENE COMPOUNDS AND THEIR USE THE UNIVERSITY OF EDINBURGH (GB) 2009-09-17 — — WO disclosed
EP-1644320-B1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS LILLY CO ELI (US) 2008-01-16 — — EP disclosed
US-7265246-B2 Indane derivates as muscarinic receptor agonists ELI LILLY AND COMPANY (US) 2007-09-04 — — US disclosed
US-20070060587-A1 Indane derivates as muscarinic receptor agonists ELI LILLY AND COMPANY (US) 2007-03-15 — — US disclosed
CN-1922172-A Substituted heterocyclic compounds and uses thereof ASTRAZENECA AB (SE) 2007-02-28 — — CN disclosed
EP-1644320-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-04-12 — — EP disclosed
WO-2005009941-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368096-A1 Fused Heterobicyclic Antiviral Agents HAVCR2, HDGF, SLC10A1 CA1 3381/4885CA2 2689/4885CA12 2826/4885
US-20240351984-A1 INDOLINE COMPOUNDS FOR INHIBITING KIF18A KIF18A, KIF18B, KIF2C CA1 3796/4885CA2 3528/4885CA12 4214/4885
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 CA1 4865/4885CA2 4760/4885CA12 4756/4885
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 CA1 2941/4885CA2 3110/4885CA12 3538/4885
US-20070060587-A1 Indane derivates as muscarinic receptor agonists CHRM1, CHRM3, CHRM2 CA1 1165/4885CA2 1373/4885CA12 1753/4885
US-20260008780-A1 SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES NOD1, NLRP3, CASP1 CA1 1281/4885CA2 1258/4885CA12 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.